Summary & Overview
CPT 88120: Urinary Tract In Situ Hybridization, Manual Morphometric Analysis
CPT code 88120 denotes an in situ hybridization (ISH) laboratory procedure on a urinary tract specimen using three to five molecular probes for manual morphometric analysis of cellular structures. This code captures a technically detailed molecular pathology test that supports diagnosis and monitoring of urothelial and other urinary tract cellular abnormalities. Nationally, accurate coding for complex cytogenetic and molecular morphology tests like 88120 affects payment, reporting consistency, and the integration of molecular data into clinical decision-making.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the service, typical sites of performance, and the role of the procedure in diagnostic workflows. The publication outlines benchmarks and coverage considerations where available, highlights common billing modifiers used with this type of technical laboratory service, and summarizes implications for laboratory and pathology service lines.
This briefing is intended for laboratory managers, billing and coding specialists, and health policy analysts seeking a national-level summary of the code, its clinical application, and the administrative considerations associated with high-complexity molecular morphology testing.
Billing Code Overview
CPT code 88120 describes a laboratory in situ hybridization (ISH) procedure performed on a urinary tract specimen. The procedure uses three to five molecular probes for manual morphometric analysis to evaluate the number and form of cellular structures within the specimen.
Service type: Technical laboratory molecular pathology test (manual morphometric ISH)
Typical site of service: Clinical laboratory or hospital pathology laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of recurrent urinary tract symptoms and a prior abnormal cytology presents for evaluation of possible urothelial carcinoma. A urine specimen is collected and sent to the pathology laboratory for molecular cytogenetic evaluation. In the laboratory, a histology/laboratory analyst performs in situ hybridization on cells from the urinary tract specimen using three to five molecular probes for manual morphometric analysis to assess copy number changes and cellular morphology. The workflow includes specimen accessioning, fixation and slide preparation, probe hybridization, fluorescence or chromogenic signal development, manual morphometric counting of signals and cellular structures, pathologist review of technical results, and generation of a technical report. Typical indications include abnormal urine cytology, hematuria with suspicion for urothelial neoplasm, surveillance after prior bladder cancer, or equivocal cytology requiring adjunct molecular testing. Typical site of service is a clinical pathology laboratory within a hospital or independent diagnostic laboratory, billed as a laboratory technical service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
TC | Technical component | When billing for the laboratory technical component only (instrumentation, technician work, supplies). |
26 |